Inhaled Staccato loxapine begins Phase IIb trial in migraine
This article was originally published in Scrip
AlexzaPharmaceuticals has started a Phase IIb study of its inhaled Staccato product, AZ-104 (loxapine), in patients with migraine. It is a lower-dose formulation of AZ-004 (also loxapine), which is in late Phase III development for the acute treatment of agitation in schizophrenia or bipolar disorder.
You may also be interested in...
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.
Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.